N (%) | AUS | DEN | NLD | RUS | |
---|---|---|---|---|---|
n (%) | |||||
Cases | 1620 (100) | 643 (39.7) | 774 (47.8) | 101 (6.2) | 102 (6.3) |
Males | 902 (55.7) | 367 (57.1) | 435 (56.2) | 59 (58.4) | 41 (40.2)a |
Median age (min–max) | 63.0 years (18.1–88.0) | 62.6 years (18.1–85.4) | 64.3 years (50.0–75.8) | 62.0 years (37.0–88.0) | 56.5 yearsa (34.0–86.0) |
Cancer | 184 (11.4) | 27 (14.7) | 91 (49.5) | 17 (9.2) | 49 (26.6) |
Males | 97 (52.7) | 14 (51.9) | 52 (57.1) | 10 (58.8) | 21 (42.9) |
Median age (min–max) | 67.2 years (35.0–88.0) | 66.2 years (45.7–81.1) | 68.7 years (50.1–75.2) | 70.0 years (37.0–88.0) | 62.0 yearsa (35.0–86.0) |
Stage I | 41 (22) | 7 (17.1) | 20 (48.8) | 3 (7.3) | 11 (26.8) |
Stage II | 57 (31) | 9 (15.8) | 20 (35.1) | 7 (12.3) | 21 (36.8) |
Stage III | 51 (28) | 5 (9.8) | 35 (68.6) | 4 (7.8) | 7 (13.7) |
Stage IV | 33 (18) | 6 (18.2) | 16 (48.5) | 3 (9.1) | 8 (24.2) |
Unstaged | 2 (1%) | 0 (–) | 0 (–) | 0 (–) | 2 (100) |
Adenoma | 616 (38.0) | 332 (53.9) | 197 (32.0) | 52 (8.4) | 35 (5.7) |
Males | 387 (62.8) | 207 (62.3) | 131 (66.5) | 33 (63.5) | 16 (45.7)a |
Median age (min–max) | 63.5 years (33.7–85.4) | 64.1 years (33.7–85.4) | 64.1 years (50.0–75.8) | 62.4 years (51.0–75.0) | 56.1 yearsa (34.0–82.0) |
Advanced | 337 (54.7) | 147 (44.3) | 149 (75.6) | 38 (73.1) | 3 (8.6) |
Non-advanced | 279 (45.3) | 185 (55.7) | 48 (24.4) | 14 (26.9) | 32 (91.4) |
HGDb | 35 (5.7) | 15 (4.5) | 18 (9.1) | 2 (3.8) | 0 (0) |
LGDb | 549 (89.1) | 317 (95.5) | 179 (90.9) | 18 (34.6) | 35 (100) |
No neoplasia | 820 (50.6%) | 284 (34.6) | 486 (59.3) | 32 (3.9) | 18 (2.2) |
Males | 418 (51.0) | 146 (51.4) | 252 (51.9) | 16 (50.0) | 4 (22.2)a |
Median age (min–max) | 60.0 years (18.0–85.0) | 56.7 years (18.0–85.0) | 62.2 years (50.0–75.0) | 61.6 years (52.0–75.0) | 47.5 yearsa (36.0–59.0) |